Search

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Jun 10 2016 Posted in Press releases

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Does the patient with myelofibrosis feel better through Pacritinib?

Jun 12 2015 Posted in Press releases

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Lighting the Flame program phases

A full guide to what our Lighting the Flame program involves, including dates of upcoming online workshops and in-person retreats.

EHA-SFH Joint membership

We are pleased to inform that EHA and the Société Française d’Hématologie (SFH) have joined forces and are offering you the possibility of an EHA-SFH Joint Membership in 2024.

Specialized Working Group Grants

EHA provides financial support to small research projects initiated by our specialized working groups (SWGs).

Register here!

Registration fee includes:

Access to all scientific and educational sessions of the meeting
Networking opportunities during breaks
Coffee breaks on October 18-20 and lunch on October 19

All fees include VAT.

Publications

Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review
Neuendorff NR, Khan A, Ullrich F, Yates S, Devarakonda S, Lin RJ, von Tresckow B, Cordoba R, Artz A, Rosko AE. J Geriatr Oncol. 2024 Feb 29;15(3):101734.